Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers

被引：90

作者：

Sansone-Parsons, A

Krishna, G

Calzetta, A

Wexler, D

Kantesaria, B

Rosenberg, MA

Saltzman, MA

机构：

[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA

[2] Pkwy Res Ctr Inc, N Miami, FL USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 05期

关键词：

D O I：

10.1128/AAC.50.5.1881-1883.2006

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We conducted a randomized, crossover study in healthy adults to examine the effects of a nutritional supplement (Boost Plus) on posaconazole pharmacokinetics. In this study, coadministration of posaconazole with Boost Plus increased the maximum concentration of posaconazole in serum and area under the concentration-time curve from 0 to 72 h values 3.4- and 2.6-fold, respectively, compared to those for the fasted state.

引用

收藏

页码：1881 / 1883

页数：3

相关论文

共 12 条

[1] Refractory coccidioidomycosis treated with posaconazole [J].

Anstead, GM ;

Corcoran, G ;

Lewis, J ;

Berg, D ;

Graybill, JR .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (12) :1770-1776

[2] Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease [J].

Courtney, R ;

Sansone, A ;

Smith, W ;

Marbury, T ;

Statkevich, R ;

Martinho, M ;

Laughlin, M ;

Swan, S .

JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (02) :185-192

[3] Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men [J].

Courtney, R ;

Radwanski, E ;

Lim, J ;

Laughlin, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :804-808

[4] Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults [J].

Courtney, R ;

Wexler, D ;

Radwanski, E ;

Lim, J ;

Laughlin, M .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (02) :218-222

[5] In vitro susceptibilities of zygomycetes to conventional and new antifungals [J].

Dannaoui, E ;

Meletiadis, J ;

Mouton, JW ;

Meis, JFGM ;

Verweij, PE .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :45-52

[6] Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi [J].

Diekema, DJ ;

Messer, SA ;

Hollis, RJ ;

Jones, RN ;

Pfaller, MA .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (08) :3623-3626

[7] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956

[8]

Gibaldi M, 1982, Pharmacokinetics, V15

[9] Disposition of posaconazole following single-dose oral administration in healthy subjects [J].

Krieter, P ;

Flannery, B ;

Musick, T ;

Gohdes, M ;

Martinho, M ;

Courtney, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) :3543-3551

[10] Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi:: Report from SENTRY Antimicrobial Surveillance Program, 2000 [J].

Pfaller, MA ;

Messer, SA ;

Hollis, RJ ;

Jones, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1032-1037